Nasarox (Oxymetazoline Hydrochloride)

Oxymetazoline is a selective alpha‑adrenergic agonist. When applied to the nasal mucosa, it stimulates alpha receptors on blood vessels, causing vasoconstriction. This reduces swelling of the nasal lining, opens the airway, and provides rapid decongestion.

The appropriate dose of Nasarox is determined by a healthcare professional. Typically, the label advises one or two sprays per nostril every 12 hours, not exceeding three days of continuous use, but the exact regimen should follow the prescriber’s instructions.

Safety data for oxymetazoline in pregnancy and lactation are limited. Women who are pregnant, planning pregnancy, or breastfeeding should consult their physician before using Nasarox to weigh potential benefits against any possible risks.

To order Nasarox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nasarox’s active ingredient, oxymetazoline, provides rapid, long‑lasting vasoconstriction compared with older agents like phenylephrine. It is generally more effective for short‑term relief, but like all decongestants, it should not be used beyond three days to avoid rebound congestion.

Store Nasarox at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and keep it out of reach of children.

Nasarox is applied topically to each nostril using the spray pump. The user tilts the head slightly forward, inserts the tip into the nostril, and presses the pump to deliver the recommended number of sprays. Avoid blowing the nose immediately after use.

Serious risks, though rare, include significant elevation of blood pressure, cardiac arrhythmias, and severe nasal ulceration. Persistent or worsening symptoms such as headache, palpitations, or nasal bleeding should prompt immediate medical attention.

Nasarox should be avoided by individuals with known hypersensitivity to oxymetazoline or any formulation components, children under six years of age unless directed by a physician, and patients with severe hypertension, coronary artery disease, or uncontrolled thyroid disorders without medical supervision.